Zylox-Tonbridge to Acquire Germany’s Optimed, Accelerating Global Vascular Expansion

Zylox-Tonbridge to Acquire Germany’s Optimed, Accelerating Global Vascular Expansion

By, Admin 19 January 2026

Zylox-Tonbridge, a Hong Kong-listed medical technology company, has signed a definitive agreement to acquire Optimed Medizinische Instrumente GmbH, a Germany-based vascular device specialist.

The transaction will be executed in multiple steps. Zylox-Tonbridge has the option to acquire 100% equity in Optimed from existing shareholders.

Who Is Optimed—and Why It Matters?

Founded in 1996 and headquartered in Ettlingen, Germany, Optimed focuses on minimally invasive vascular and endourology devices.

Over nearly 30 years, Optimed has built:

  • Sales and service coverage across 70+ countries
  • Deep relationships with European physicians and key opinion leaders
  • One of the most comprehensive peripheral venous stent portfolios globally

Its venous stents target complex anatomies, including:

  • Iliofemoral veins
  • Iliac bifurcation
  • Vena cava

Strong Clinical Evidence

Optimed’s products are backed by high-quality clinical data, including:

  • sinus-Venous trial
  • STEVECO trial, the first prospective, randomized, multicenter study in chronic deep venous obstruction

The STEVECO trial showed significant improvements in quality of life and clinical severity versus conservative treatment.

Strategic Rationale Behind the Acquisition

The acquisition creates a fully integrated global platform across R&D, manufacturing, and commercialization.

Key strategic advantages include:

  • Faster global product launches
  • Expanded access to European clinical expertise
  • Stronger presence beyond mainland China

Following closing, Zylox-Tonbridge will integrate sales, marketing, and customer service into one global commercial organization.

Rüdiger Hausherr will remain CEO of Optimed and report to Dr. Jonathon Zhong Zhao, Chairman and CEO of Zylox-Tonbridge.

Leadership Commentary

Dr. Jonathon Zhong Zhao called the acquisition a milestone in Zylox-Tonbridge’s global strategy.

He emphasized combining complementary product portfolios and manufacturing platforms to deliver innovative and affordable vascular solutions worldwide. Optimed CEO Rüdiger Hausherr highlighted the need to evolve amid changing healthcare dynamics.

He noted the partnership enables Optimed to scale faster by leveraging Zylox-Tonbridge’s R&D and manufacturing strength. Westlake Partners, Optimed’s investor, described Zylox-Tonbridge as a fast-growing multinational with strong roots in China and proven global execution.

Key Transaction Benefits

1. Accelerated Global Expansion

  • Strengthens Zylox-Tonbridge’s footprint in Europe and international markets
  • Diversifies product portfolio and global distribution

2. Integrated Global Commercialization

  • Combines two complementary sales networks
  • Supports faster clinical development and efficient launches

3. Manufacturing and Operational Synergies

  • Integrated production across Germany and China
  • Expanded German manufacturing ensures high-quality, reliable supply for Europe

4. Scaled Global R&D Impact

  • Enables Zylox-Tonbridge to extend its high-efficiency R&D globally
  • Supports a sustained pipeline of advanced vascular solution

Company Snapshot

Zylox-Tonbridge Medical Technology Co., Ltd.

  • Founded: 2012
  • Headquarters: Hangzhou, China
  • Focus: Vascular interventional medical devices

Optimed Medizinische Instrumente GmbH

  • Founded: 1996
  • Headquarters: Ettlingen, Germany
  • Focus: Minimally invasive vascular and endourology devices
  • Global leader in venous stenting

Bottom Line

This acquisition positions Zylox-Tonbridge as a truly global vascular device player, combining European clinical leadership with China-based R&D and manufacturing scale.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!